- Mankhwala
- Umboni
- Neuroblastoma
- Chotupa Cholimba
- Umboni
- TILS
- Chithandizo cha Maselo a NK
- Myasthenia Gravis (MG)
- Khansa ya m'magazi ya Lymphoblastic (B-ALL)
- Systemic Lupus Erythematosus (SLE)
- Matenda a khansa ya m'magazi (T-ALL)
- Non Hodgkin Lymphoma (NHL)
- Matenda a Myeloma Yambiri (MM)
- Kufalitsa Lymphom Yaikulu ya B-cell
- B-lymphocytic Leukemia
- Myeloma
Chithandizo cha CAR-T cha Multiple Myeloma (MM)
Chidule
Multiple Myeloma (MM) ndi mtundu wa khansa womwe umakhudza maselo a m'magazi m'mafupa. Umadziwika ndi zovuta zake komanso zosiyanasiyana, zomwe nthawi zambiri zimapangitsa kuti munthu abwerere m'mbuyo komanso asalandire chithandizo chamankhwala chachikhalidwe. Ngakhale kuti chemotherapy, kusamutsa maselo oyambira, ndi mankhwala atsopano zakhala ndi zotsatira zabwino, odwala ambiri pamapeto pake amakumana ndi kukana chithandizo. Chithandizo cha CAR-T (Chimeric Antigen Receptor T-cell) ndi chithandizo chodziwika bwino chomwe chakhala chikugwira ntchito bwino pochiza multiple myeloma yomwe yabwereranso m'mafupa komanso yomwe yakana chithandizo, kupereka yankho labwino kwa odwala omwe ali ndi njira zochepa.
Kodi chithandizo cha CAR-T cha MM n'chiyani?
Chithandizo cha CAR-T chimaphatikizapo kusintha maselo a T a wodwala kuti azindikire bwino ndikuukira maselo a khansa. Pa ma myeloma angapo, maselo a CAR-T amapangidwa kuti ayang'ane BCMA (B-cell maturation antigen), puloteni yomwe imapezeka pamwamba pa maselo a myeloma. Pambuyo posinthidwa majini, maselo a T awa amabwereranso m'thupi la wodwalayo, komwe amafunafuna ndikuwononga maselo a khansa, zomwe zingayambitse kuchira komanso kupulumuka kwa nthawi yayitali.
Ubwino Waukulu wa Chithandizo cha CAR-T cha Multiple Myeloma
- Kugwira Ntchito Kwambiri mu Relapsed/Refractory MMChithandizo cha CAR-T chakhala chikuyenda bwino kwambiri mwa odwala omwe ali ndi matenda a myeloma ambiri omwe abwereranso kapena omwe sachira, nthawi zambiri amapeza mpumulo wathunthu kapena matenda ochepa otsalira (MRD).
- Kulondola Koyenera: Mwa kuyang'ana BCMA, chithandizo cha CAR-T chimaukira maselo a myeloma molondola, kuteteza minofu yathanzi ndikuchepetsa zotsatirapo zoyipa poyerekeza ndi mankhwala wamba.
- Zapadera komanso ZatsopanoChithandizochi chimagwiritsa ntchito maselo a T a wodwalayo, zomwe zimathandiza kuti pakhale dongosolo la chithandizo lopangidwa mwapadera kwambiri. Izi zimathandizanso kuchepetsa chiopsezo chokana chithandizo.
- Kukhululukidwa Kwanthawi Yaitali: Odwala ambiri omwe amalandira chithandizo cha CAR-T amalandira chithandizo cholimba, ndipo ena amakhalabe ndi mpumulo kwa zaka zambiri, ngakhale njira zina zitalephera.
Njira Yothandizira
- Kusonkhanitsa maselo a T: Gawo loyamba limaphatikizapo kusonkhanitsa maselo a T kuchokera m'magazi a wodwalayo pogwiritsa ntchito leukapheresis, njira yofanana ndi kupereka magazi.
- Kupanga maselo a T: Maselo a T awa amatumizidwa ku labotale, komwe amasinthidwa majini kuti afotokoze CAR yeniyeni ya BCMA, zomwe zimawonjezera luso lawo lozindikira ndikupha maselo a myeloma.
- Kulowetsedwa kwa Maselo a CAR-T: Pambuyo pokulitsa mu labu, maselo a T opangidwa amabwereranso m'magazi a wodwalayo kudzera mu IV.
- Kuyang'anira ndi Kubwezeretsa: Pambuyo polandira mankhwala, odwala amawunikidwa kuti awone ngati pali zotsatirapo zina monga cytokine release syndrome (CRS) kapena neurotoxicity. Zotsatirapozi nthawi zambiri zimatha kuthetsedwa ndi chithandizo chamankhwala komanso kuyang'aniridwa.
Nchifukwa chiyani muyenera kusankha chithandizo cha BIOOCUS's CAR-T cha Multiple Myeloma?
- Ukadaulo Wamakono wa CAR-TBIOOCUS imagwiritsa ntchito njira zamakono zopititsira patsogolo ukadaulo wa CAR-T kuti iwonetsetse kuti odwala a MM alandira chithandizo chapamwamba kwambiri komanso zotsatira zabwino kwambiri.
- Ukatswiri Wachipatala Wapamwamba Padziko LonseGulu lathu la akatswiri mu hematology ndi immunotherapy limapereka chisamaliro chapadera, kuonetsetsa kuti wodwala aliyense akulandira chithandizo chabwino kwambiri cha matenda ake apadera.
- Mbiri Yotsimikizika: Tathandiza odwala ambiri a MM ndi chithandizo cha CAR-T, ndipo ambiri apeza mpumulo wodabwitsa komanso wokhalitsa.
- Thandizo Lonse kwa Odwala Padziko LonseBIOOCUS imapereka chithandizo chokwanira kwa odwala ochokera kumayiko ena, kukutsogolerani mu gawo lililonse la chithandizo, kuyambira pa upangiri woyamba mpaka chisamaliro chothandizidwa pambuyo pa chithandizo.
Umboni Wachipatala ndi Mitengo Yopambana
-
Umboni Wachipatala ndi Mitengo Yopambana
Chithandizo cha CAR-T cha myeloma yambiri chawonetsa zotsatira zabwino kwambiri m'mayesero azachipatala komanso m'malo enieni. Makamaka, chakhala chothandiza kwa odwala omwe abwereranso kuchipatala atalandira chithandizo chamitundu yambiri, ndipo ena akupeza mpumulo wathunthu kapena kukhala opanda MRD.
- Nkhani ya Wodwala: Kupeza Chikhululukiro Cha Nthawi Yaitali ndi CAR-T ya Multiple Myeloma
- Phunziro la Nkhani: Yankho Lonse Pambuyo pa Chithandizo cha CAR-T mu Myeloma Yobwerezabwereza Yomwe Yabwereranso
- Kugwira Ntchito kwa Chithandizo cha CAR-T Pochiza Myeloma Yobwerera M'mbuyo/Yosasinthika
Kafukufukuyu akuwonetsa momwe chithandizo cha CAR-T chikusinthira malo ochizira matenda a myeloma yambiri, kupatsa odwala chiyembekezo cha kupulumuka kwa nthawi yayitali komanso kukhala ndi moyo wabwino.
Deta Yachipatala
Zizindikiro za CD19+20CAR-T:Odwala omwe ali ndi B-cell non Hodgkin's lymphoma
| Mtengo wa CR wa mwezi umodzi | Mtengo wa PR wa mwezi umodzi | Mtengo wa OR wa mwezi umodzi | CRS≥3 | CRES≥3 |
| 71.95% (59/82) | 25.6 (21/82) | 97.55(80/82) | 12.19% (10/82) | 0 |
Zizindikiro za CD19+22CAR-T:Chithandizo cha odwala omwe ali ndi vuto la khansa ya m'magazi ya B-lymphocytic omwe abwereranso ku CD19 komanso omwe ali ndi vuto la kuchepa kwa magazi m'thupi
| Mtengo wa CR wa mwezi umodzi | Mtengo wa PR wa mwezi umodzi | Mtengo wa OR wa mwezi umodzi | CRS≥3 | CRES≥3 |
| 92.1% (35/38) | 7.9% (3/38) | 100% (38/38) | 15.79% (6/38) | 0 |
Zizindikiro za BCMACAR-T:Chithandizo cha myeloma yambiri yobwereranso komanso yokana
| Mtengo wa CR wa mwezi umodzi | Mtengo wa PR wa mwezi umodzi | Mtengo wa OR wa mwezi umodzi | CRS≥3 | CRES≥3 |
| 72.41% (21/29) | 27.59% (8/29) | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.



